Expertise in
21
conditions

Dr. Andrei R. Shustov

Hematology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Expertise in
21
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Andrei Shustov is a Hematologist practicing medicine in Seattle, Washington.

Dr. Shustov is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 92 peer reviewed articles and participating in 8 clinical trials. Dr. Shustov is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WA

Languages Spoken

English
German
Portuguese
Russian
Ukrainian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Premera
  • EPO
  • PPO

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Lenalidomide
Study Phase: Phase 2
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other
Study Drugs: High Dose Chemotherapy, Autologous Stem Cell Transplant, Romidepsin
Study Phase: Phase 2
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: July 27, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: October 10, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Enrollment Status: Completed
Publish Date: July 08, 2019
View 7 Less Clinical Trials

92 Total Publications

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Journal: Blood cancer journal
Published: January 28, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Farsi, Hebrew, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mazyar Shadman is a Hematologist practicing medicine in Seattle, Washington. Dr. Shadman is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Shadman is currently accepting new patients.

Expertise in
18
conditions
Dr. Chaitra Ujjani
Hematology | Oncology
Expertise in
18
conditions
Dr. Chaitra Ujjani
Hematology | Oncology
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-606-1955
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chaitra Ujjani is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Ujjani is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Ujjani is currently accepting new patients.

Expertise in
10
conditions
Dr. Petros Grivas
Hematology | Oncology
Expertise in
10
conditions
Dr. Petros Grivas
Hematology | Oncology
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-520-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Petros Grivas is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Grivas is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Endoscopy. Dr. Grivas is currently accepting new patients.

Frequently Asked Questions about Dr. Andrei R. Shustov

How do I make an appointment with Dr. Andrei R. Shustov?

You can book an appointment with Dr. Andrei R. Shustov by calling their office at 855-557-0555. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrei R. Shustov a top-rated expert for Peripheral T-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrei R. Shustov is classified as an Elite expert for Peripheral T-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrei R. Shustov specialize in?

While Dr. Andrei R. Shustov is a Hematology, they have specific expertise in Peripheral T-Cell Lymphoma, T-Cell Lymphoma, and Anaplastic Large Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Andrei R. Shustov participate in research or clinical trials?

Yes. Dr. Andrei R. Shustov has published 92 articles and abstracts on conditions like Peripheral T-Cell Lymphoma. You can view a list of Dr. Andrei R. Shustov's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrei R. Shustov accept my insurance?

Dr. Andrei R. Shustov accepts most major insurance plans, including Anthem BCBS and Premera. We recommend calling the office directly at 855-557-0555 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shustov's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile